Lung squamous cancer can be treated with immunotherapy when other treatments are not satisfactory and genetic testing is performed to be sensitive to immunotherapy. Conventional treatments for squamous lung cancer are surgery, chemotherapy, radiotherapy, targeted therapy and other treatments, and some patients still have disease progression after these treatments. These patients who are sensitive to immunotherapy can consider immunotherapy, which can also be combined with chemotherapy and targeted therapy, depending on the patient’s prior efficacy. The addition of immunotherapy also increases the probability and extent of adverse reactions, which should be evaluated with attention to timely assessment and early management. After immunotherapy, patients also need to be evaluated on a regular basis to assess how well the treatment is working, including whether symptoms are in remission, quality of life is improving, and whether the lesions are getting smaller.